content_image/247708.jpg content_image/247711.jpg content_image/247712.jpg
While the LifeMark transaction was the feature event of the year, the ongoing business model continued to pay dividends for our shareholders. Eliminating the gains from the LifeMark transaction, the following table gives a snapshot of the 2011 fiscal year: 

<img src='content_image/247708.jpg'>

## 2011 In Review 

The first half of 2011 was spent negotiating the LifeMark transaction and also sourcing, negotiating and structuring new partnerships through which we would contribute the proceeds from LifeMark. In June 2011, Alaris received proceeds of $65 million for a reduction of our interest in LifeMark and disposition of our interest in MediChair. Through the course of the next six months of 2011, Alaris contributed more than $76 million in two new partnerships as well as a further contribution to a current partner. The net result of those transactions was a significant increase in our distributable cash per share as well as a dramatic change in the diversification of our revenue stream. The following chart gives an excellent look at how our revenue stream has been diversified over the past twelve months: 

<img src='content_image/247711.jpg'>

<img src='content_image/247712.jpg'>

